Side-by-side · Research reference

MatrixylvsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED9/39 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Matrixyl

Thymalin

Primary target

Dermal fibroblastsPaccola 2025

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

—

Origin

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Matrixyl

Thymalin

Formulation concentration

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

—

Application frequency

Twice daily (AM/PM)

Standard cosmeceutical protocol.

—

Duration

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

5–10 day cycles, 1–2× per year

In vitro evidence

Fibroblast viability + ECM gene upregulationPaccola 2025

—

Vehicle

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

—

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Frequency

—

Once daily during cycle

Lower / starter dose

—

2.5 mg / day

Evidence basis

—

Russian clinical + in vitroKhavinson 2002

Reconstitution

—

Saline or bacteriostatic water

Timing

—

Morning preferred

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

Matrixyl

Thymalin

Irritation

Mild erythema, pruritus in sensitive skin (rare)

—

Allergic reaction

Contact dermatitis (uncommon)

Rare hypersensitivity to bovine-derived polypeptide

Systemic absorption

Negligible — topical application only

—

Injection site reaction

—

Mild erythema at IM site

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Matrixyl

·Active dermatitis or open wounds at application site

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Matrixyl

Thymalin

1. Cleanse

Wash face with gentle cleanser. Pat dry.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Application

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

Intramuscular — deltoid or gluteal. Rotate sites.

3. Timing

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

Morning preferred during cycle.

4. Storage

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Needle

—

23–25G, 25–38 mm IM needle.

06Stack Synergy

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001